Sectors
RNXT
RenovoRx, Inc.
0.86
5 x 0.82
5 x 0.98
bid
ask
-
0.02
1.99%
11:07 AM
timesize
| Ytd | 2.38% | |
| 1y | -32.80% |
0.86
day range
0.89
0.70
52 week range
1.45
| Open | 0.86 | Prev Close | 0.88 | Low | 0.86 | High | 0.89 | Mkt Cap | 32.67M |
| Vol | 46.00K | Avg Vol | 266.54K | EPS | -0.32 | P/E | -2.74 | Forward P/E | -3.10 |
| Beta | 0.99 | Short Ratio | 3.43 | Inst. Own | 8.18% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 0.89 | 200-d Avg | 0.95 | 1yr Est | 5.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-13 | 2024-09 | -0.12 | -0.1 | 0.02 | 16.67% |
| 2024-08-13 | 2024-06 | 0 | N/A | N/A | N/A |
| 2024-08-13 | 2024-06 | 0 | -0.1 | N/A | N/A |
| 2024-05-10 | 2024-03 | 0 | N/A | N/A | N/A |
| 2024-05-10 | 2024-03 | 0 | -0.07 | N/A | N/A |
| 2024-04-01 | 2023-12 | 0 | -0.17 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-10 | Ascendiant Capital | Upgrade | Buy | Buy |
| 2024-09-12 | Ascendiant Capital | Upgrade | Buy | Buy |
| 2024-06-17 | Ascendiant Capital | Upgrade | Buy | |
| 2024-02-02 | Alliance Global Partners | Upgrade | Buy | |
| 2023-11-15 | Maxim Group | Downgrade | Buy | Hold |
| 2023-08-18 | Roth MKM | Upgrade | Buy | Buy |
Profile
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-01-25 | AGAH RAMTIN M.D. | Officer and Director | 47.46K | Purchase |
| 2024-01-25 | BAGAI SHAUN R. | Chief Executive Officer | 292.54K | Purchase |
| 2024-01-25 | MACFARLANE KIRSTEN ANGELA | Director | 40.98K | Purchase |
| 2024-01-25 | MARTON LAURENCE | Director | 33.63K | Purchase |
| 2023-10-02 | NELMS ANGELA GILL | Chief Operating Officer | 1.10K | Purchase |
| 2024-01-25 | SPIEGEL ROBERT J | Director | 40.98K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Bank of Montreal /CAN/ | 975.00K | 1.24M | 4.06% |
| 2024-09-29 | Adar1 Capital Management, LLC | 315.19K | 400.29K | 1.31% |
| 2024-09-29 | Geode Capital Management, LLC | 232.94K | 295.83K | 0.97% |
| 2024-09-29 | Nixon Peabody Trust Company | 97.17K | 123.40K | 0.40% |
| 2024-09-29 | Millennium Management Llc | 82.35K | 104.59K | 0.34% |
| 2024-09-29 | Vanguard Group Inc | 56.74K | 72.06K | 0.24% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Extended Market Index Fund | 137.40K | 174.50K | 0.57% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 56.74K | 72.06K | 0.24% |
| 2024-07-30 | Schwab Capital Trust-Total Stock Market Index Fund | 49.23K | 62.52K | 0.21% |
| 2024-10-30 | Fidelity Total Market Index Fund | 47.28K | 60.04K | 0.20% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 32.38K | 41.12K | 0.13% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 3.79K | 4.82K | 0.02% |